Who makes [14C]TAK-935 IV Infusion?

[14C]TAK-935 IV Infusion is developed by Takeda.

What development phase is [14C]TAK-935 IV Infusion in?

[14C]TAK-935 IV Infusion is in Phase 1.

Last reviewed 2026-04-19 · How we verify

[14C]TAK-935 IV Infusion

Takeda · Phase 1 active Small molecule

At a glance

Generic name	[14C]TAK-935 IV Infusion
Also known as	OV935
Sponsor	Takeda
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[14C]TAK-935 IV Infusion CI brief — competitive landscape report
[14C]TAK-935 IV Infusion updates RSS · CI watch RSS
Takeda portfolio CI